(Q34442253)

2 August 2017

Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy (English)

1 reference

2 August 2017

0 references

Kevin A Peterson

11

0 references

Hertzel C. Gerstein

object named as

Hertzel C Gerstein

5

0 references

John Buse

object named as

John B Buse

9

0 references

Emily Chew

17

object named as

Emily Y Chew

1 reference

2 August 2017

18

ACCORD Study Group

1 reference

2 August 2017

3

David C Goff

1 reference

2 August 2017

Walter T Ambrosius

1

1 reference

2 August 2017

Ronald P Danis

2

1 reference

2 August 2017

Craig M Greven

4

1 reference

2 August 2017

Robert M Cohen

6

1 reference

2 August 2017

Matthew C Riddle

7

1 reference

2 August 2017

Michael E Miller

8

1 reference

2 August 2017

Denise E Bonds

10

1 reference

2 August 2017

Yves D Rosenberg

12

1 reference

2 August 2017

Letitia H Perdue

13

1 reference

2 August 2017

Barbara A Esser

14

1 reference

2 August 2017

Lea A Seaquist

15

1 reference

2 August 2017

James V Felicetta

16

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

2 August 2017

1 reference

2 August 2017

128

1 reference

2 August 2017

3

1 reference

2 August 2017

312-318

1 reference

Rosiglitazone and delayed onset of proliferative diabetic retinopathy

2 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Diabetic macular edema associated with glitazone use.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Diabetic retinopathy in a multi-ethnic cohort in the United States

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Rosiglitazone (Avandia) and macular edema

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Partial resolution of diabetic macular oedema after systemic treatment with furosemide

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Macular edema and retinal hard exudates in African Americans with type 1 diabetes: the New Jersey 725.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE).

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Rosiglitazone and cardiotoxicity--weighing the evidence

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Rosiglitazone--continued uncertainty about safety

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010554

Rosiglitazone and cardiovascular risk

9 December 2018

1 reference

12 December 2020

The record on rosiglitazone and the risk of myocardial infarction

1 reference

12 December 2020

Rosiglitazone: seeking a balanced perspective

1 reference

12 December 2020

Model-checking techniques based on cumulative residuals

1 reference

12 December 2020

New visual acuity charts for clinical research

1 reference

12 December 2020

The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema

1 reference

12 December 2020

Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group

1 reference

12 December 2020

The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema

1 reference

12 December 2020

Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group

1 reference

12 December 2020

The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate

1 reference

12 December 2020

The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema

1 reference

12 December 2020

10.1001/ARCHOPHTHALMOL.2009.310

Identifiers

DOI

1 reference

2 August 2017

1 reference

2 August 2017

1 reference